Canada, RSV and Moderna
To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...
Preliminary data were announced from 2 clinical trials evaluating Arexvy in a broader population of adults at increased for RSV disease.
Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.
With cold and flu season around the corner, Doctors recommend receiving the RSV vaccine ahead of the holidays.
The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...
RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...
This summer, the FDA approved Moderna's mRESVIA RSV vaccine for adults. Last year, the FDA approved Abrysvo (Pfizer) and Arexvy (GSK) to protect seniors from serious illness, and approved ...
New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.
GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 50 ...
This update in the health sector highlights major developments including DiaSorin's significant profit growth, GSK's RSV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback